Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.
Ontology highlight
ABSTRACT: Treatment options for triple-receptor negative (ER-/PR-/Her2-) and Her2-overexpressing (ER-/PR-/Her2+) breast cancers with acquired or de novo resistance are limited, and metastatic disease remains incurable. Targeting of growth signaling networks is often constrained by pathway redundancy or growth-independent cancer cell cycles. The cell-cycle protein Cdc7 regulates S phase by promoting DNA replication. This essential kinase acts as a convergence point for upstream growth signaling pathways and is therefore an attractive therapeutic target. We show that increased Cdc7 expression during mammary tumorigenesis is linked to Her2-overexpressing and triple-negative subtypes, accelerated cell cycle progression (P < 0.001), arrested tumor differentiation (P < 0.001), genomic instability (P = 0.0
SUBMITTER: Rodriguez-Acebes S
PROVIDER: S-EPMC2947297 | biostudies-literature | 2010 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA